PPD combines medical affairs team with real-world research subsidiary Evidera

PPD adds its medical affairs research operations to evidence-based solutions subsidiary Evidera.

PPD has put its medical affairs research operations (MARO) team under Evidera, the real-world research-focused subsidiary PPD bought last year.

The new unit, with Evidera’s name, will still be focusing on real-world research for regulatory approval, as well as market access communications and consulting.

“Our focus is to better anticipate post-approval requirements in order to further enhance trial designs and increase the efficiency and effectiveness of providing crucial data for market access activities,” PPD’s spokeperson Randy Buckwalter told FierceCRO.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Buckwalter said the company has seen a great deal of collaboration and alignment between the two organizations since PPD’s acquisition of Evidera last August.

This new unit “combines Evidera’s multidisciplinary scientific and consulting expertise to design studies, analyze findings and communicate outcomes, with PPD’s global operational infrastructure to manage and implement both interventional and observational studies,” he said.

Some other services it provides include health modeling and simulation to help analyze a drug’s economic value and impact, expanded access or compassionate use, clinical outcome assessments, safety and risk management, etc.

Jon Williams, president and CEO of Evidera since 2013, will lead the new unit. The members previously with the two teams will continue to work at their current locations, so the reorganization is more operational than physical, according to Buckwalter.

PPD also unveiled a new logo for Evidera in conjunction with the announcement.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.